Ibandronate sodium

Names

[ Name ]:
Ibandronate sodium

[Synonym ]:
Sodium hydrogen {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonate
BM 21.0955Na
boniva
Natriumhydrogen-{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonat
Phosphonic acid, (1-hydroxy-3-(methylpentylamino)propylidene)bis-, monosodium salt
SodiuM Ibandronate
hydrogène {1-hydroxy-3-[méthyl(pentyl)amino]-1-phosphonopropyl}phosphonate de sodium
Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt (1:1)
phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-, monosodium salt
sodium,hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate
Ibandronate sodium

Biological Activity

[Description]:

Ibandronate Sodium is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.Target: OthersIbandronate (1.25-2 μM) significantly reduces endothelial cell growth, while ibandronate (2 μM) also significantly reduces capillary-like tube formation and increases apoptosis of endothelial cells. Ibandronate (< 100 μM) dose-dependently increases VEGF expression in endothelial cells [1]. Ibandronate (< 100 μM) inhibits growth of both prostate cancer cell lines (LNCaP and PC-3) in a dose dependent manner [2].Ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months) significantly reduces the risk of new morphometric vertebral fractures by 62% and 50% (p = 0.0006), respectively, in osteoporotic women after 3 years' treatment. Ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months) significantly and progressively increases BMD of lumbar spine by 6.5% and 5.7%, respectively, in osteoporotic women after 3 years' treatment [3]. Ibandronate (< 125 mg/kg s.c.) results in a dose dependent increase in bone mineral density (BMD), trabecular bone volume and trabecular number, load to failure (Fmax), and yield load in long bones and vertebrae in ovariectomized rats, and increased trabecular separation in ovariectomized rats is fully prevented by all doses [4].

[Related Catalog]:

Signaling Pathways >> Others >> Others

Research Areas >> Others

[References]

[1]. Morgan, C., S. Jeremiah, and J. Wagstaff, Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. Microvasc Res, 2009. 78(3): p. 453-8.

[2]. Epplen, R., et al., Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. Acta Oncol, 2011. 50(1): p. 127-33.

[3]. Chesnut, I.C., et al., Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004. 19(8): p. 1241-9.

[4]. Bauss, F., et al., Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol, 2002. 29(10): p. 2200-8.

[Related Small Molecules]

Chemical & Physical Properties

[ Boiling Point ]:
587.8ºC at 760 mmHg

[ Molecular Formula ]:
C₉H₂₂NNaO₇P₂

[ Molecular Weight ]:
341.211

[ Flash Point ]:
309.3ºC

[ Exact Mass ]:
341.076904

[ PSA ]:
160.98000

[ LogP ]:
0.93820

[ Appearance of Characters ]:
white

[ Vapour Pressure ]:
2.88E-16mmHg at 25°C

[ Storage condition ]:
2-8°C

[ Water Solubility ]:
H2O: >10mg/mL

MSDS

Click to get detail MSDS

Safety Information

[ RIDADR ]:
NONH for all modes of transport

[ RTECS ]:
SZ8563300